ABOUT THE FAIR
Antibody Engineering & Therapeutics Europe is Europe’s leading conference and exhibition dedicated to the next generation of therapeutic antibodies. It serves as a unique platform for cutting-edge research, clinical development, and biopharmaceutical innovation. As the European edition of the renowned U.S.-based event Antibody Engineering & Therapeutics, the conference brings together experts from academia, industry, and regulatory authorities to showcase, discuss, and translate the latest advancements in antibody technology into clinical application.
The event is held annually and rotates among leading European centers of scientific research and innovation. It is organized by Informa Connect, a division of the globally active Informa PLC, specializing in high-level business events in knowledge-intensive sectors.
The program focuses on highly specialized topics spanning the entire value chain of modern antibody therapeutics—from the discovery of new targets and innovative selection methods to binding formats, bispecific and multispecific antibodies, and non-IgG-based constructs. Central themes also include antibody-drug conjugates (ADCs), novel payload strategies, and the application of artificial intelligence and machine learning for the design and optimization of next-generation therapeutics.
Another key focus is the translation of preclinical research into clinical applications, alongside the manufacturing and formulation of biological agents, and the exploration of new therapeutic areas beyond oncology—such as immunology, neurology, and autoimmune diseases.
Exhibitors include companies from the biotechnology and pharmaceutical industries, academic and non-academic research institutions, as well as specialized service providers such as CROs, CMOs, and technology vendors in bioprocess development. Innovations showcased at the event include cutting-edge in vitro and in vivo models, Fc-engineering platforms, therapeutic scaffolds, agonists for combination therapies, and advanced production and analytical methods for complex biologics.
The event primarily attracts heads of research, clinical developers, C-level decision-makers, and technical experts from biopharma, academic research, and regulatory bodies—bringing together exactly those stakeholders shaping the future of therapeutic antibodies.
As part of the global Antibody Engineering & Therapeutics series, with additional editions in the United States and Asia, the European event offers not only scientific excellence but also a strategically international platform.
Each host city offers excellent connectivity via international airports and public transportation, as well as an inspiring setting for high-level networking, scientific exchange, and the cultivation of long-term partnerships.
The Antibody Engineering & Therapeutics Europe take place annually, and therefore presumably in May 2027 in Basel.